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Yuki Kagoya,1 Keisuke Kataoka,1 Yasuhito Nannya,1 Mineo Kurokawa1,2Acute kidney injury (AKI) is a common complication after allogeneic stem cell transplantation (SCT).
Although various risk factors for AKI have been reported, the influence of pretransplant comorbidity on
the incidence of AKI has not been well investigated. We performed a retrospective analysis of 207 consec-
utive patients undergoing myeloablative or nonmyeloablative SCT between 2001 and 2009, using the hema-
topoietic cell transplantation-specific comorbidity index (HCT-CI) as a representative of pretransplant
comorbidities. According to Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) criteria, 158 pa-
tients (76.3%) developed AKI, and 92 patients (44.4%) developed severe AKI (RIFLE class I or class F) within
100 days after SCT. The cumulative incidence of severe AKI within 100 days in patients with an HCT-CI score
0, 1-2, and$3 was 21.3%, 48.8%, and 73.9%, respectively. In multivariate analysis, the HCT-CI was indepen-
dently associated with severe AKI (HCT-CI 1-2: adjusted hazard ratio [HR] 2.42, P\.01; HCT-CI $3: ad-
justed HR 4.69, P \ .01). In a landmark analysis, patients with severe AKI had a lower 3-year overall
survival (OS) (39.3% versus 61.4%, P\.01), and a higher 3-year nonrelapse mortality (NRM) (40.8% versus
5.6%, P\.01) than those without AKI. Multivariate analysis showed that severe AKI was a significant risk
factor for worse OS (HR: 2.10, P 5 .01) and NRM (HR: 6.15, P\.01). Thus, it is important to assess the
HCT-CI to predict the incidence of AKI, which is a strong indicator of worse prognosis after SCT.
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poietic stem cell transplantationINTRODUCTION
Allogeneic stem cell transplantation (SCT) is a po-
tentially curative treatment modality for hematologic
malignancies and nonneoplastic diseases. However,
various treatment-related toxicities limit the long-
term survival of patients undergoing SCT. Among
those toxicities, acute kidney injury (AKI) is one of the
most common complications after transplantation [1].
AKI usually occurs within the first 100 days, and its
development leads to increased mortality, especially af-
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6/j.bbmt.2010.07.010[2-4]. In allogeneic SCT recipients, AKI is associated
with various posttransplant complications, including
severe bacterial or fungal infections, viral infections
such as cytomegalovirus (CMV) reactivation, acute
graft-versus-host disease (aGVHD), engraftment
syndrome, or veno-occlusive disease (VOD) [2,5-9].
In addition, various medications prescribed during
transplantation, including calcineurin inhibitors and
several antibiotic or antifungal agents, such as
amphotericin-B or vancomycin, contribute to renal
dysfunction [1,10,11].
On the other hand, the relationship between pre-
transplant comorbidities and the development of
AKI after SCT has not been elucidated enough. Re-
cently, the hematopoietic cell transplantation-specific
comorbidity index (HCT-CI) was developed to pre-
dict the outcome of patients undergoing SCT accord-
ing to their pretransplant comorbidities [12]. Several
retrospective studies have shown that the HCT-CI
score is a significant prognostic factor for overall
survival (OS) and nonrelapse mortatality (NRM)
following allogeneic SCT [13,14]. However, it has
been unknown whether the HCT-CI has an impact
on the development of various transplant-related
complications, such as AKI.
Biol Blood Marrow Transplant 17:394-400, 2011 395The HCT-CI Predicts AKI after SCTIn the present study, we aimed to examine the in-
cidence of AKI and to investigate the pretransplant
and posttransplant risk factors for AKI after allogeneic
SCT, using the HCT-CI as an indicator of pretrans-
plant comorbidities. In addition, using a landmark
analysis, we assessed the impact of AKI on OS and
NRM in allogeneic SCT recipients.
PATIENTS AND METHODS
Patients
We retrospectively analyzed 207 consecutive adult
patients ($16 years old) who underwent allogeneic
MA or nonmyeloablative (NMA) SCT at the Univer-
sity of Tokyo Hospital, Japan, between October
2001 and March 2009. Patients’ data were collected
by reviewing medical records and computer database
system. The following baseline characteristics were re-
corded: sex, age, disease risk, donor types (related or
unrelated), stem cell sources (peripheral blood, bone
marrow, or umbilical cord blood), HCT-CI scores,
previous histories of SCT, and conditioning regimens.
The HCT-CI score was calculated in each patient and
classified into low-risk (score 0), intermediate-risk
(score 1-2), and high-risk (score $3) groups. Patients’
diseases were diagnosed according to the WHO
classification. Standard-risk diseases included acute
leukemia in the first or second complete remission,
chronic myelogenous leukemia in the first or second
chronic phase, myelodysplastic syndrome in refractory
anemia, refractory anemia with ringed sideroblasts, or
refractory cytopenia with multilineage dysplasia, se-
vere aplastic anemia, chemosensitive lymphoma, and
multiple myeloma. All the other conditions were de-
fined as high-risk diseases. This study was performed
in accordance with the Helsinki Declaration and ap-
proved by the Ethics Committee of the University
of Tokyo Hospital. All patients provided written in-
formed consent for retrospective data exploitation.
Stem Cell Transplantation Procedure
MA conditioning regimens consisted of cyclophos-
phamide (60 mg/kg/day for 2 days) plus fractionated
total body irridiation (TBI) (12 Gy), or busulfan (1
mg/kg every 6 hours for 4 days) plus cyclophosphamide
(60mg/kg/day for 2 days).NMA conditioning regimens
consisted of fludarabine based regimens with or without
low-dose TBI (4 Gy). GVHD prophylaxis was per-
formed with calcineurin inhibitors (cyclosporine [CsA]
or tacrolimus) with short-term methotrexate. Infection
prophylaxis was performed with quinolone, azole, and
acyclovir.
Definitions of Acute Kidney Injury
Renal function was assessed by serum creatinine
concentration and urine output. AKI was defined andclassified into 3 categories, class risk (R), injury (I),
or failure (F), according to the Risk, Injury, Failure,
Loss, and End-stage kidney disease (RIFLE) criteria
[15]. Class R corresponded to$1.5-fold increase in se-
rum creatinine or a reduction in urine output (oliguria
of\0.5 mL/kg/h.6 hours); Class I,$2-fold increase
in serum creatinine or a reduction in urine output (oli-
guria of\0.5 mL/kg/h .12 hours); Class F, $3-fold
increase in serum creatinine, an absolute serum creat-
inine $4 mg/dL with an acute rise of at least 0.5 mg/
dL, or a reduction in urine output (oliguria of\0.3
mL/kg/h .24 hours or anuria .12 hours). In each
case, baseline serum creatinine was measured before
beginning of the conditioning regimen, and the worst
RIFLE stage within 100 days after SCT was deter-
mined. We ruled out renal dysfunction considered to
be associated with multiple organ dysfunction syn-
dromes when it was the last event before death. In
this analysis, class I or F was considered as severe
AKI, in accordance with the previous report [16].
The following posttransplant events were noted:
aGVHD, veno-occlusive disease (VOD), cytomegalo-
virus (CMV) reactivation, and sepsis. Sepsis was de-
fined as the condition with bacteremia complicated
with systemic inflammatory response syndrome
(SIRS). SIRS was defined as the occurrence of at least
2 of the following criteria: fever.38.0C or hypother-
mia\36.0C, tachycardia .90 beats/minute, tachyp-
nea .20 breaths/minute, leukocytosis .12  109/L
or leukopoenia\4  109/L. Blood culture was per-
formed when patients become febrile or the treating
physicians suspected bacteremia. The use of nephro-
toxic drugs, such as amphotericin B (AMPH-B), lipo-
somal amphotericin B (L-AMB), or vancomycin was
recorded. The trough level of CsA or tacrolimus was
measured at least twice a week during the first 30
days after SCT and once a week thereafter until 100
days after SCT. It was considered as nephrotoxic if
the concentration was above 300 ng/mL in CsA or
20 ng/mL in tacrolimus before the date of the highest
serum creatinine concentration [17,18]. The primary
causes of AKI were determined by the treating
physician at the time of SCT, where infection was
defined as when the treating physician considers that
the patients have infectious diseases, such as sepsis,
pneumonia, or meningitis from their signs and symp-
toms or radiologic findings.Statistical Analysis
Cumulative incidence of AKI during the first 100
days was calculated in a competing risk model, in
which relapse of the primary diseases or death from
any cause was considered as a competing risk. All the
variables were used as categoric variables and ex-
pressed as the numbers and proportions. The time to
the development of severe AKI was calculated from
396 Biol Blood Marrow Transplant 17:394-400, 2011Y. Kagoya et al.the date of transplantation to the date of the incidence
of severe AKI. Patients alive without severe AKI dur-
ing the 100 days were censored at day 100 and patients
who died without developing severe AKI were cen-
sored at the time of death. For univariate analyses of
pretransplant risk factors for developing severe AKI,
the log-rank test was performed using the time to se-
vere AKI as the endpoint. In addition, the impact of
posttransplant factors, including aGVHD, sepsis,
CMV reactivation, and use of AMPH-B, L-AMB, or
vancomycin, on the development of severe AKI was
analyzed as a time-dependent covariate in a Cox pro-
portional hazards model. The multivariate analysis of
each pre-and posttransplant variable for the develop-
ment of severe AKI was assessed by a Cox proportional
hazards model, in which the factors with P # .1 in the
univariate analysis were included. Posttransplant fac-
tors were treated as time-dependent covariates in the
analysis. As for calcineurin inhibitors, the proportion
of patients with nephrotoxic concentrations at the
time of highest creatinine level was investigated in
each group with or without severe AKI and comparedTable 1. Pretransplant and Posttransplant Characteristics of 207
Classified According to the Occurrence of Acute Kidney Injury
Variable No AKI (n 5 51) Class
Pretransplant factors
Sex
Male 27 (52.9) 39
Age
$50 years 19 (37.3) 19
<50 years 32 (62.7) 45
Disease risk
Standard 27 (52.9) 37
High 24 (47.1) 27
Donor
Related 27 (52.9) 27
Unrelated 24 (47.1) 37
Stem cell source
Bone marrow 28 (54.9) 41
Peripheral blood 22 (43.1) 21
Umbilical cord blood 1 (2.0) 2
Prior stem cell transplantation 4 (7.8) 5
Conditioning regimen
Myeloablative 37 (72.5) 53
Non-myeloablative 14 (27.5) 11
HCT-CI
Low-risk (score 0) 27 (52.9) 32
Intermediate-risk (score 1-2) 21 (41.2) 23
High-risk (score $3) 3 (5.9) 9
Posttransplant factors
Acute graft-versus-host disease
Grade 0-2 43 (84.3) 56
Grade 3-4 8 (15.7) 8
CMV reactivation
Positive 20 (39.2) 29
Negaitive 31 (60.8) 35
Sepsis 6 (11.8) 7
Medications
AMPH-B or L-AMB 0 (0.0) 2
Vancomycin 36 (70.6) 47
Calcineurin inhibitor toxicity 19 (37.3) 34
HCT-CI indicates hematopoietic cell transplantation-specific comorbidity ind
cytomegalovirus.with Fisher’s exact test. To assess the outcomes of
patients who developed AKI with respect to the con-
trol group, the analysis of OS and NRM was carried
out by a landmark approach, in which the follow-up
was started at the onset of AKI class R or severe AKI
in patients who developed AKI class R or severe AKI,
and at the median time of the incidence of AKI in pa-
tients who did not develop AKI. OS was depicted by
the Kaplan-Meier curve, whereas NRM was depicted
by the cumulative incidence curve, in which relapse
of the primary disease was considered as a competing
risk. Cox regression model or competing regression
model was used to estimate adjusted hazard ratios
for multivariate analysis of OS or NRM, respectively.RESULTS
Patient Characteristics and Incidence of AKI
There were 207 adult patients who underwent
allogeneic SCT from October 2001 to March 2009,
of which MA SCT was performed in 149 patientsPatients Undergoing Allogeneic Stem Cell Transplantation
R (n 5 64) AKI Class I (n 5 57) Class F (n 5 35)
(60.9) 34 (59.6) 27 (77.1)
(29.7) 24 (42.1) 14 (40.0)
(70.3) 33 (57.9) 21 (60.0)
(57.8) 32 (56.1) 12 (34.3)
(42.2) 25 (43.9) 23 (65.7)
(42.2) 26 (45.6) 13 (37.1)
(57.8) 31 (54.4) 22 (62.9)
(64.1) 29 (50.9) 15 (42.9)
(32.8) 21 (36.8) 13 (37.1)
(3.1) 7 (12.3) 7 (20.0)
(7.8) 5 (8.8) 2 (5.7)
(82.8) 37 (64.9) 22 (62.9)
(17.2) 20 (35.1) 13 (37.1)
(50.0) 10 (17.5) 6 (17.1)
(35.9) 29 (50.9) 13 (37.1)
(14.1) 18 (31.6) 16 (45.7)
(87.5) 54 (94.7) 26 (74.3)
(12.5) 3 (5.3) 9 (25.7)
(45.3) 8 (14.0) 5 (14.3)
(54.7) 49 (86.0) 30 (85.7)
(10.9) 15 (26.3) 10 (28.6)
(3.1) 1 (1.8) 2 (5.7)
(73.4) 45 (78.9) 25 (71.4)
(53.1) 29 (50.9) 16 (45.7)
ex; AMPH-B, amphotericin B; L-AMB, liposomal amphotericin B; CMV,
Figure 1. Cumulative incidence curves of AKI and severe AKI within
100 days after allogeneic stem cell transplantation. SCT indicates stem
cell transplantation; AKI, acute kidney injury.
Biol Blood Marrow Transplant 17:394-400, 2011 397The HCT-CI Predicts AKI after SCTand NMA SCT in 58 patients. Baseline characteristics
and posttransplant complications of patients in each
RIFLE stage are summarized in Table 1. In our
cohort, no patients had renal dysfunction defined by
the HCT-CI scoring system (pretransplant creatinine
.2.0 mg/dL) before transplantation. Overall, AKI de-
veloped in 158 of 207 patients (76.3%) and severe AKI
in 92 patients (44.4%). Cumulative incidence at 100
days after SCT was 75.4% (95% confidence interval
[CI]: 68.9%-80.7%) in AKI and 44.4% (95% CI:
37.6%-51.1%) in severe AKI (Figure 1). According
to RIFLE classification, 64 patients (30.9%) developed
class R, 57 patients (27.5%) class I, and 35 patients
(16.9%) class F. Themedian interval to the occurrence
of severe AKI was 30 days after SCT.
AKI: Risk Factors and Etiology
Univariate analysis showed that severe AKI patients
more often received NMA conditioning regimens (P\
.01), underwent umbilical cord blood transplantation
(P\ .01), and had higher HCT-CI scores (P\ .01).
They had higher incidence of aGVHD grade III-IV
(P 5 .09), sepsis (P\ .01), and need of AMPH-B, L-
AMB (P 5 .04), or vancomycin use (P\ .01) (Table
2). The cumulative incidence of severe AKI in patients
who were on low risk, intermediate risk, or high risk in
HCT-CI score was 21.3% (95% confidence interval
[CI]: 12.9%-31.2%), 48.8% (95% CI: 37.8%-58.9),
73.9% (95% CI: 58%.2-84.5%), respectively
(Figure 2). As for calcineurin inhibitors, there was no
difference in a proportion of patients with high trough
level between groups with or without severe AKI
(P 5 .78).
Multivariate analysis of risk factors for AKI revealed
that theHCT-CI score (intermediate risk: adjusted haz-
ard ratio [HR] 2.42, 95% CI 1.33-4.40; P\ .01, high
risk: HR 4.69, 95% CI 2.74-8.92; P\ .01), umbilical
cord transplantation (HR 2.07, 95% CI 1.09-3.93),
NMA conditioning regimen (HR 1.82, 95% CI 1.13-
2.93), sepsis (HR 2.66, 95% CI 1.59-4.44), and use of
vancomycin (HR 1.79, 95% CI 1.04-3.10; P 5 .04)
were independently associated with the development
of severe AKI (Table 2). Infection was the most com-
mon cause of AKI in our cohort (n5 34 (37.0%). Other
causes of AKI included aGVHD in 19 patients
(20.7%), calcineurin inhibitor toxicity in 14 patients
(15.2%), antibiotics or antifungal agents in 11 patients
(12.0%), engraftment syndrome in 2 patients (2.2%),
thrombotic microangiopathy in 2 patients (2.2%),
CMV reactivation in 1 patient (1.1%), and others in
9 patients (9.8%).
OS and NRM
In total, 101 of 207 patients (48.8%) died, of which
52 patients (51.5%) died of nonrelapse causes. Accord-
ing to the cause of death, 24 patients died directlybecause of severe AKI within 100 days after SCT,
consisting of 2 patients (8.3% of the 24 patients who
relapsed within 100 days after SCT) and 22 patients
(12.0% of the 183 patients who did not relapse within
100 days after SCT). There was no significant differ-
ence in the proportions of severe AKI as a mortality
cause between patients with or without relapse (P5 1.0).
The median follow-up period of surviving patients
was 37 months (range: 6-94 months). The landmark
analysis of OS and NRM according to the severity of
AKI showed the differences among patients without
AKI, with AKI class R, and severe AKI (Figure 3).
The 3-year OS was 61.4% (95% CI: 48.1%-78.4%)
in patients without AKI, 53.9% (95% CI: 42.4%-
68.6%) in patients with AKI class R, and 39.3%
(95% CI: 30.2%-51.1%) in patients with severe AKI
(P \ .01). The 3-year NRM was 5.6% (95% CI:
0.9%-17.0%) in patients without AKI, 16.6% (95%
CI: 8.4%-27.2%) in patients with AKI class R, and
40.8% (95% CI: 30.5-50.7%) in patients with severe
AKI (P\ .01).
Multivariate analysis of OS demonstrated that the
high-risk HCT- CI score (adjusted HR 1.83, 95% CI
1.01-3.29; P 5 .04) and high-risk diseases (adjusted
HR 2.44, 95% CI 1.58-3.77; P\ .01) were indepen-
dently associated with worse OS as pretransplant pre-
dictors. As for NRM, the high-risk HCT-CI (adjusted
HR 2.95, 95% CI 1.26-6.92, P 5 .01) independently
predicted increased NRM as a pretransplant factor.
Among posttransplant complications, severe AKI was
significantly associated with both OS (adjusted HR
2.10, 95% CI 1.18-3.76; P 5 .01) and NRM (adjusted
HR 6.15, 95% CI 1.95-19.43, P\ .01) (Table 3).DISCUSSION
AKI is one of the major complications associated
with allogeneic SCT. In the previous studies, acute
Table 2. Pre- and Posttransplant Factors Associated with the
Incidence of Severe Acute Kidney Injury following Allogeneic
Stem Cell Transplantation: Multivariate Analysis
Univariate Multivariate
P value
Adjusted Hazards
Ratio (95%
Confidence
Interval) P-Value
Pretransplant factors
Sex .10
Male 0.99 (0.63-1.55) .95
Age .20
$50 years
Disease risk .13
High disease risk
Donor .45
Related
Stem cell source <.01
Peripheral blood 0.86 (0.53-1.40) .55
Umbilical cord blood 2.07 (1.09-3.93) .03
Prior stem cell
transplantation
.80
Conditioning regimen <.01
Myeloablative
conditioning regimen
0.55 (0.34-0.89) .01
HCT-CI <.01
Intermediate-risk
(score 1-2)
2.42 (1.34-4.40) .01
High-risk (score $3) 4.69 (2.47-8.92) <.01
Posttransplant factors
Acute graft-versus-host disease
Grade 3-4 .09 1.09 (0.53-2.22) .82
CMV reactivation
Positive .42
Sepsis <.01 2.66 (1.59-4.44) <.01
Medications
AMPH-B or L-AMB .04 2.30 (0.63-8.44) .21
Vancomycin <.01 1.79 (1.04-3.10) .04
HCT-CI indicates hematopoietic cell transplantation-specific comorbid-
ity index; AMPH-B, amphotericin B; L-AMB, liposomal amphotericin B;
CMV, cytomegalovirus.
Figure 2. Cumulative incidence curves of severe AKI within 100 days
after allogeneic stem cell transplantation according to the HCT-CI.
SCT indicates stem cell transplantation; HCT-CI, hematopoietic cell
transplantation-specific comorbidity index.
398 Biol Blood Marrow Transplant 17:394-400, 2011Y. Kagoya et al.renal failure (usually defined as 2-fold increase in
serum creatinine) has been reported to occur in 36%
to 80% of patients after MA SCT, and in 33% to
56% after NMA SCT [1,2,4-6,8,19,20]. Although
the incidence of AKI after MA SCT is usually higher
than that after NMA SCT, it is widely distributed
according to the reports. One explanation for such
a wide range of AKI incidence might be because of
the differences in patients’ pretransplant backgrounds.
Indeed, in the previous studies, hypertension present
at transplantation has been reported as a significant
risk factor for AKI afterMASCT [20]. Similarly, diabe-
tes mellitus and pretransplant renal dysfunction have
been pointed out as risk factors of AKI after NMA
SCT [8,21]. However, there have been few studies
that comprehensively assessed pretransplant comorbi-
dities and investigated their impact on the occurrence
of AKI. Although Parikh et al. [4] examined whether
Charlson Comorbidity Index (CCI) score could predict
the occurrence of AKI after SCT, the effect of thisscore was only borderline significant (HR: 1.37, 95%
CI 1.0-1.9).
Recently, the HCT-CI score was created to pre-
dict NRM in allogeneic SCT recipients, and has
been shown to have a better discriminatory power
for NRM than CCI score [12]. Thus, we investigated
the influence of the HCT-CI on the incidence of
AKI, and revealed, for the first time, that patients
with a high HCT-CI score had more frequently severe
AKI after SCT. In addition, we found that the most
important predictor of the development of severe
AKI was the highHCT-CI score. Although, in a previ-
ous study, the HCT-CI score was not identified as
a risk factor for AKI [22], that study included only
patients undergoing NMA SCT. In contrast, in the
present analysis, 149 of 207 patients (72.0%) under-
went MA SCT. Because MA conditioning regimens
predispose patients to muchmore organ toxicities, pre-
transplant comorbidity might play a more significant
role in the development of various complications, in-
cluding AKI, for patients undergoing MA SCT, com-
pared with patients undergoing NMA SCT.
As for posttransplant factors, various complica-
tions, including aGVHD, sepsis, or CMV reactivation,
have been reported to have correlation with AKI [5-9].
In this study, we demonstrated for the first time
that sepsis was independently associated with the
development of severe AKI by time-dependent analy-
sis. In addition, we investigated the effect of nephro-
toxic antibiotics, antifungal agents and revealed use
of vancomycin was associated with the development
of severe AKI. Because vancomycin has been reported
to increase the risk of nephrotoxicity, especially in high
trough levels, it may have contributed to the incidence
of AKI after SCT [11]. However, there is a possibility
that infectious complications weremore severe in cases
that require vancomycin use, which might have
Figure 3. Kaplan-Meier estimation by landmark analysis for overall sur-
vival (A) and cumulative incidence of nonrelapse mortality (B) after allo-
geneic stem cell transplantation according to the severity of acute kidney
injury. SCT indicates stem cell transplantation; AKI, acute kidney injury.
Biol Blood Marrow Transplant 17:394-400, 2011 399The HCT-CI Predicts AKI after SCTcontributed to more frequent renal dysfunction. Al-
though a calcineurin inhibitor was 1 of the main causes
of AKI in this study, the high trough concentration of
calcineurin inhibitors was not correlated with severe
AKI. This may indicate that the toxic concentration
of CsA or tacrolimus widely varies among patients,Table 3. Pre- and Posttransplant Factors Associated with Overall
Allogeneic Stem Cell Transplantation: Multivariate Analysis
Overall Survival
Hazard ratio
(95% Confidecne Interval)
AKI class R 1.14 (0.61-2.10)
Severe AKI 2.10 (1.18-3.76)
Male 1.22 (0.80-1.90)
Age $50 years 1.61 (0.97-2.65)
HCT-CI
Intermediate-risk (score 1-2) 1.13 (0.66-1.91)
High-risk (score $3) 1.83 (1.01-3.29)
High disease risk 2.44 (1.58-3.77)
Related donor 1.21 (0.56-2.64)
Myeloablative conditioning regimen 0.74 (0.42-1.29)
Stem cell source
Peripheral blood 1.02 (0.47-2.19)
Umbilical cord blood 1.49 (0.71-3.15)
Prior stem cell transplantation 1.05 (0.51-2.17)
AKI indicates acute kidney injury; HCT-CI, hematopoietic cell transplantation-and it is difficult to define uniform cutoff value to
predict AKI. Therefore, it is important to judge the
acceptable concentration limit for individual patients.
As for prognosis, although posttransplant AKI
might have attenuated the predictive powerof pretrans-
plant factors, high-risk diseases were associated with
worse OS, and high-risk HCT-CI with worse OS and
NRM, as reported previously [12]. As a posttransplant
complication, we showed that the occurrence of severe
AKI was strongly associated with lower OS and higher
NRM, whereas OS and the NRM of the patients with
AKI class R was not significantly worse than without
AKI, as is consistent with the previous studies
[3,22,23]. Thus, RIFLE classification system can well
stratify patients into risk groups with different
prognoses. It has been shown that this classification is
useful for stratifying risks for mortality because of
AKI, especially in critical care settings [24]. Because
of its simplicity and ability of good stratification, the
criteriamight alsobeused in the areaof transplantation.
Further, 24 deaths of the 101 mortality cases (23.8%)
were caused by severe AKI, which included the patients
with or without relapse almost equally. Therefore, se-
vere AKI is a significant factor leading to death even
in cases of early relapse. In other words, we need to
note that organ malfunction could be a major cause of
death, regardless of the status of the primary disease.
Because of terrible prognosis in patients with severe
AKI, it is important to prevent it, especially in patients
with pretransplant risk factors, like the the high HCT-
CI score. Further, because sepsis is a significant post-
transplant risk factor for severe AKI, it is crucially
important to control infectious complications at early
times following SCT.
Our studyhad several limitations. First, because this
is a retrospective analysis, our findings are subject to un-
measured pretransplant or posttransplant confounding
factors. They might have had some influence on theSurvival and Nonrelapse Mortality in the Patients Undergoing
Non-relapse Mortality
P-Value
Hazard ratio
(95% Confidecne Interval) P-Value
.69 2.31 (0.64-8.31) .2
.01 6.15 (1.95-19.43) <.01
.39 1.44 (0.71-2.92) .32
.06 1.02 (0.47-2.20) .97
.66 1.14 (0.50-2.62) .76
.04 2.95 (1.26-6.92) .01
<.01 1.19 (0.65-2.20) .58
.62 0.86 (0.30-2.51) .79
.29 0.53 (0.23-1.23) .14
.97 0.59 (0.18-1.88) .37
.29 1.40 (0.63-3.12) .41
.89 0.81 (0.27-2.42) .71
specific comorbidity index.
400 Biol Blood Marrow Transplant 17:394-400, 2011Y. Kagoya et al.present results. Second,wedidnot analyze the influence
of each factor included in theHCT-CI score on the de-
velopment of AKI in detail. There is a possibility that
a particular component of the HCT-CI have a strong
impact on AKI after SCT. Third, we do not have de-
tailed informationon chronicGVHD,whichmay affect
the prognosis of OS or NRM.
In summary, we found AKI is a common complica-
tion after allogeneic SCT, and high HCT-CI scores,
particularly $3, was the most important predictor of
severe AKI. The development of severe AKI was inde-
pendently associated with worse prognosis, whereas
the occurrence of AKI class R did not have a strong
impact on OS. Therefore, the strategy to prevent the
occurrence of life-threatening severe AKI in patients
with a high HCT-CI score would be imperative to
improve their survival after allogeneic SCT.ACKNOWLEDGMENTS
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